International Alpha Thalassemia Consortium

The International Alpha Thalassemia Consortium, hosted by the UCSF Center for Maternal-Fetal Precision Medicine, brings together an interdisciplinary group of clinicians and scientists from around the world to focus expertise in hematology, maternal-fetal medicine, genetics, fetal therapy, and neonatology on alpha thalassemia major (ATM).

We gather quarterly in a virtual seminar to share advances, challenges, and best practices regarding clinical care for prenatal, pediatric, and adult patients diagnosed with ATM.

All are welcome.

Next Quarterly Seminar

 November 2022 – Date & Time TBD

Past Seminars

August 23, 2022


  • Three-pronged approach to develop gene therapies to cure alpha thalassemia major ex vivo
  • In-depth look at CRISPR/AAV6-mediated genome editing correction strategy
  • Future directions that include the potential adaptation of successful ex vivo strategies for in utero and postnatal in vivo delivery


May 9, 2022





February 22, 2022


  • Patients registry demographics
  • Outcomes in patients that pursued fetal therapy
  • Silver linings: unintended outcomes from referring provider collaborations


November 30, 2021


  • Risk of iron overload and its related complications in alpha thalassemia patients
  • Standard of care practices for iron overload monitoring
  • Review the currently available options for iron chelation


August 17, 2021


  • How and when to initiate invasive diagnostics and transfusion therapy in fetuses suspected to have alpha thalassemia
  • Technical aspects of determining how much to transfuse, the frequency of transfusions, and the role and technical considerations for fetal exchange transfusion
  • Troubleshooting strategies for difficult cases such as fetuses requiring transfusion at early gestational ages


May 20, 2021


  • current practices in hematopoietic stem cell transplantation for ATM, and upcoming advances that improve survival of babies with ATM



ATM Patient Registry & Clinical Trial

To refer a patient to the patient registry or clinical trial, please contact


The aim of this registry is to prospectively and retrospectively collect data on patients who are diagnosed with alpha thalassemia major (ATM) and other alpha thalassemia mutations. Data collected will be used to:

  1. Understand the natural history of the disease
  2. Identify patient outcomes of therapies
  3. Improve clinical management of patients with ATM
  4. Improve medical decision making
  5. Improve quality of care


Clinical trial to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with ATM, performed at the time of in utero transfusion of red blood cells.

Learn more about this trial at the UCSF Fetal Treatment Center.